TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 7.1% – Should You Sell?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIWGet Free Report)’s share price was down 7.1% during mid-day trading on Monday . The company traded as low as $1.30 and last traded at $1.30. Approximately 120 shares traded hands during trading, a decline of 98% from the average daily volume of 5,093 shares. The stock had previously closed at $1.40.

TriSalus Life Sciences Stock Performance

The business has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $1.31.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

Further Reading

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.